Nicole Sullivan counsels clients regarding worldwide portfolio management and strategic development. Her practice involves domestic and international patent drafting and prosecution focused primarily in biotechnology, pharmaceutical, bioengineering biologics, and life sciences. Her practice also involves due diligence investigations as well as freedom to operate and patentability opinions. In addition, her practice also includes Hatch-Waxman litigations and the inter partes reexaminations.
Prior to practicing law, Nicole was a scientific advisor at an international patent law firm, and a senior research scientist at Wyeth Pharmaceuticals. At Wyeth she worked in research and development in the Department of Pain's Molecular Pharmacology Group and served as a program leader for two drug discovery targets.
Nicole is co-author of several peer-reviewed scientific articles and has presented her research at national and regional scientific conferences. She also received a Pharmaceutical Research and Manufacturers of America Foundation's Advanced Predoctoral Fellowship in Pharmacology/Toxicology to support her predoctoral thesis work.
Nicole's pharmacology and industry background allows her to understand and assist industry clients with complex legal and scientific issues.
- Pharmaceutical companies — domestic and international patent prosecution for both small and large molecule technologies; counseling; development of a global patent prosecution strategy and portfolio maintenance; Inter Partes Review practice; freedom to operate analysis; non-infringement and invalidity opinion analysis; intellectual property due diligence review for acquisition of molecules and companies; preparation and review of license agreements
- Biopharmaceutical companies — patent prosecution of large molecule technologies; counseling; freedom to operate analysis; invalidity opinion analysis; intellectual property due diligence review of both patent portfolio and trade secret
- Life science companies — freedom to operate analysis; non-infringement and invalidity opinion analysis; Inter Partes Review practice
- Leading research university — patent drafting and prosecution of large molecule technologies and medical and life science devices; counseling; portfolio management
- Multinational imaging company — Inter Partes Review practice
- Multinational software company — preparation and review of license agreements
- Litigation — Multi-defendant Hatch-Waxman litigations (both plaintiff and generic); trade secret action; and an International Trade Commission Action
Presentations and Speaking Engagements
- CLE presentation: Developments in Establishing Personal Jurisdiction in Hatch-Waxman Cases post-Daimler (May 2015).
- NYC Bio’s Supreme Court Myriad Decision Panel Discussion – Other panel of speakers include John Murray of Tannenbaum, Helpern, Syracuse & Hirschtritt, Hans Saur of Bio (the national trade organization), Mitchell Wong of the Exeter Law Group, Laura Coruzzi of Jones Day and Kristin Neuman of MPEG LA (July 2013).
- Lunch and Learn Discussing the Supreme Court’s Decisions in Association for Molecular Pathology v. Myriad Genetics and Federal Trade Commission v Actavis, Inc. Novo Nordisk (June 2013).